Prenatal diagnosis of Fabry disease

Prenatal Diagnosis

Volumn 27, Issue 8, 2007, Pages 693-694

  Desnick, Robert J ^a,b  

^a NEW YORK UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME ASSAY; ENZYME REPLACEMENT; FABRY DISEASE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; MOLECULAR CLONING; NOTE; PHENOTYPE; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; X CHROMOSOME;

ADULT; CHORIONIC VILLI SAMPLING; FABRY DISEASE; FEMALE; FETAL DISEASES; HUMANS; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 34547731457     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.1767     Document Type: Note

References (17)

1. Banikazemi M, Bultas J, Waldek S, et al. 2007. Agalsidase beta therapy for advanced Fabry disease: A randomized trial. Ann Intern Med 146: 77-86.
2. Bernstein HS, Bishop DF, Astrin KH, et al. 1989. Fabry disease: Six gene rearrangements and an exonic point mutation in the α- galactosidase gene. J Clin Invest 83: 1390-1399.
3. Brady RO, Uhlendorf BW, Jacobson CB. 1971. Fabry's disease: Antenatal detection. Science 172: 174-175.
4. Caggana M, Ashley CA, Desnick RJ, Eng CM. 1997. Fabry disease: Molecular carrier detection and prenatal diagnosis by analysis of closely linked polymorphisms at Xq22.1. Am J Med Genet 71: 329-335.
5. Desnick R, Raman M, Bendel R, Kersey J, Lee J, Krivit W. 1973. Prenatal diagnosis of glycosphingolipidoses: Sandhoffs and Fabry's diseases. J Pediatr 83: 149.
6. Desnick RJ, Ioannou YA, Eng CM. 2001. α-galactosidase a deficiency: Fabry disease. In The Metabolic and Molecular Bases of Inherited Disease, Scriver CR, Beaudet AL, Sly WS, et al. (eds). McGraw-Hill: New York; 3733-3774.
7. Eng CM, Guffon N, Wilcox WR, et al. 2001. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Eng J Med 345: 9-16.
8. Germain PJ, Waldek S, Banikazemi M, et al. 2007. Sustained long-term renal stabilization after 54 months of agalside beta therapy in patients with Fabrty disease. J. Am. Soc. Nephrol 18: 1547-1557.
9. Kint JA. 1970. Fabry disease: alpha-galactosidase deficiency. Science 167: 1268-1269.
10. Meikle PJ, Hopwood JJ, Clague AE, et al. 1999. Prevelence of lysosomal storage disorders. J.A.M.A. 281: 249-254.
11. MacDermot KD, Holmes A, Miners AH. 2001. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38: 769-775.
12. Nakao S, Kodama C, Takenaka T, et al. 2003. Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 64: 801-807.
13. Rolfs A, Bottcher T, Zshiesche M, et al. 2005. Prevelance of Fabry disease in patients with cryptogenic stroke: A prospective study. Lancet 366: 1794-1796.
14. Sachdev B, Takenaka T, Teraguchi H, et al. 2002. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophie cardiomyopathy. Circulation 105: 1407-1411.
15. Spada M, Pagliardini S, Yasuda M, et al. 2006. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79: 31-40.
16. Thadhani R, Wolf M, West ML, et al. 2002. Patients with Fabry disease on dialysis in the United States. Kidney Int 61: 249-255.
17. Wilcox WR, Banikazemi M, Guffon N, et al. 2004. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75: 65-74.